Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07732634) titled 'RiMO-HNC-NEO1: Phase 2 Study of RiMO-301 and Hypofractionated Radiotherapy With Pembrolizumab for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer' on July 23.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: University of Illinois at Chicago
Condition:
Head and Neck Cancer
Head Cancer
Neck Cancer
Intervention:
Drug: RiMO-301
Drug: Pembrolizumab
Radiation: Radiation
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: August 2026
Ta...